论文部分内容阅读
目的分析抗真菌药物治疗甲真菌病的疗效与安全性,为临床用药提供参考依据。方法计算机检索数据库(Pub Med、CNKI等),查阅自1995年—2014年发表的有关特比萘芬、伊曲康唑、氟康唑治疗甲真菌病的相关文献。纳入随机对照试验(RCT),进行方法质量评价,使用Rev Man5.3软件进行数据分析。结果纳入17篇RCT文献,共计2694例患者。Meta分析结果显示,特比萘芬治疗甲真菌病的临床治愈率和真菌学治愈率均高于伊曲康唑和氟康唑,3组药物不良反应率差异无统计学意义。结论在纳入研究的3种抗真菌药中,特比萘芬治疗甲真菌病的疗效优于伊曲康唑和氟康唑,安全性相当。
Objective To analyze the efficacy and safety of antifungal agents in the treatment of onychomycosis and provide reference for clinical use. Methods The computer search database (Pub Med, CNKI, etc.) was reviewed and the related literature on the treatment of onychomycosis with terbinafine, itraconazole and fluconazole published from 1995 to 2014 was reviewed. Randomized controlled trials (RCTs) were included to evaluate the quality of the method and data analysis was performed using RevMan5.3 software. Results A total of 2694 patients were included in 17 RCTs. Meta analysis showed that terbinafine treatment of onychomycosis clinical cure rate and mycological cure rate were higher than itraconazole and fluconazole, three groups of adverse drug reaction rate was not statistically significant. CONCLUSION Terbinafine is superior to itraconazole and fluconazole in the treatment of onychomycosis among the three antifungal agents included in the study, with comparable safety.